Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Therapy of multiple sclerosis].

P Livrea

    Acta Neurologica
    |April 1, 1989
    PubMed
    Summary
    This summary is machine-generated.

    Recent clinical trials evaluated immunosuppressive and immunomodulating agents for multiple sclerosis treatment. These therapies, including corticosteroids and interferons, show potential for clinical practice.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Smoking in Patients with Parkinson's Disease: preliminary striatal DaT-SPECT findings.

    Acta neurologica Scandinavica·2015
    Same author

    Psychopathological comorbidities in medication-overuse headache: a multicentre clinical study.

    European journal of neurology·2015
    Same author

    Diagnostic delay in adult-onset dystonia: data from an Italian movement disorder center.

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2015
    Same author

    Action tremor in Parkinson's disease: frequency and relationship to motor and non-motor signs.

    European journal of neurology·2014
    Same author

    Effects of anodal TDCS stimulation of left parietal cortex on visual spatial attention tasks in men and women across menstrual cycle.

    Neuroscience letters·2014
    Same author

    Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression.

    European journal of neurology·2012
    Same journal

    Biological research in epileptics: accumulation of ossiaromatic substances detected with the xanthoproteic reaction of Becher.

    Acta neurologica·2010
    Same journal

    Biological research in epileptics; convulsive action of phenolic derivatives.

    Acta neurologica·2010
    Same journal

    Natural immunity and endorachid therapy; changes in blood lysozyme in relation to endorachid treatment with triod and nicotinic acid.

    Acta neurologica·2010
    Same journal

    On the weight value of the liver in prococeous dementia and in love.

    Acta neurologica·2010
    Same journal

    Human and experimental reflex epilepsy.

    Acta neurologica·2010
    Same journal

    Pharmacological research on bulbocapnine, the trend of calcium and potassium on the dog's blood serum during prolonged treatment with bulbocapnine.

    Acta neurologica·2010
    See all related articles

    Area of Science:

    • Neuroimmunology
    • Clinical Pharmacology

    Context:

    • Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
    • Current MS treatments aim to modulate the immune system to reduce disease activity and progression.

    Purpose:

    • To review and discuss the efficacy of various immunosuppressive and immunomodulating agents used in clinical trials for multiple sclerosis over the past five years.
    • To evaluate the potential clinical value of these treatments for managing multiple sclerosis.

    Summary:

    • Clinical trials investigated agents such as high-dose corticosteroids, azathioprine, cyclophosphamide, plasma exchange, linoleic acid, copolymer 1, total lymphoid irradiation, cyclosporine, and interferons.
    • The results of these trials provide insights into the effectiveness and safety profiles of these diverse therapeutic options.

    Related Experiment Videos

  • Discussion focuses on which treatments demonstrate sufficient evidence to be considered for practical application in patient care.

    • Impact:

    • Informs clinicians about the latest evidence-based treatment options for multiple sclerosis.
    • Contributes to the evolving understanding of immunomodulatory therapies in autoimmune neurological disorders.
    • Aids in personalized treatment strategies for patients with multiple sclerosis based on recent clinical findings.